Allianz Asset Management’s Travere Therapeutics TVTX Stock Holding History

Allianz Asset Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,500	Closed	-$210K	–	2108
2025 Q4	$210K	Buy	+5,500	New	+$179K	﹤0.01%	1933
2022 Q3	–	Sell	-109,513	Closed	-$2.65M	–	2128
2022 Q2	$2.65M	Buy	109,513 +45,793	+72%	+$1.15M	﹤0.01%	1317
2022 Q1	$1.64M	Buy	63,720 +3,900	+7%	+$104K	﹤0.01%	1669
2021 Q4	$1.85M	Buy	+59,820	New	+$1.68M	﹤0.01%	1645
2021 Q2	–	Sell	-14,635	Closed	-$365K	–	2485
2021 Q1	$365K	Sell	14,635 -68,985	-82%	-$1.91M	﹤0.01%	2007
2020 Q4	$2.28M	Buy	83,620 +13,507	+19%	+$315K	﹤0.01%	1276
2020 Q3	$1.29M	Sell	70,113 -6,463	-8%	-$126K	﹤0.01%	1368
2020 Q2	$1.56M	Buy	+76,576	New	+$1.22M	﹤0.01%	1702
2019 Q4	–	Sell	-34,646	Closed	-$407K	–	2843
2019 Q3	$407K	Buy	34,646 +8,540	+33%	+$141K	﹤0.01%	2439
2019 Q2	$525K	Sell	26,106 -1,669	-6%	-$33K	﹤0.01%	2330
2019 Q1	$628K	Buy	27,775 +2,625	+10%	+$58K	﹤0.01%	2250
2018 Q4	$566K	Buy	+25,150	New	+$626K	﹤0.01%	2231

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allianz Asset Management's TVTX Position: Q1 2026 in Review

Allianz Asset Management sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 5,500 shares — an estimated $210K sold.

Allianz Asset Management first reported a position in TVTX in Q4 2018 and held it in 12 quarters. The position peaked at $2.65M in Q2 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Allianz Asset Management reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
Allianz Asset Management sold 5,500 Travere Therapeutics shares in Q1 2026, an estimated $210K.
Allianz Asset Management first reported a position in Travere Therapeutics in Q4 2018 and held it in 12 quarters.
Allianz Asset Management's Travere Therapeutics position peaked at $2.65M in Q2 2022.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Allianz Asset Management's 13F filing for Q1 2026, filed 11 May 2026.